Market Overview

UPDATE: Piper Jaffray Raises PT to $118 on Edwards Lifesciences on Lower Risks Ahead

Related EW
Earnings Scheduled For October 26, 2015 (LH, BRCM, WCN, CR, JAKK, EW, SWFT, PMCS, CAKE, TMK, HIG, KN, AGII, WRB, ROP)
Edwards SAPIEN 3 Valve Demonstrates High Survival And Low Stroke Rate At 1 Year

Piper Jaffray reiterated its Overweight rating on Edwards Lifesciences (NYSE: EW) and increased its price target on shares from $90 to $118 in a research report published Friday.

Piper Jaffray noted, "We are raising our price target on EW reflecting the reduction in risk inherent with the positive national coverage decision (NCD), positive FDA panel meeting on high-risk patients, and the removal of uncertainty related to the outcome of the Supreme Court decision on the Affordable Care Act (ACA)."

Edwards Lifescience closed at $104.44 on Thursday.

Latest Ratings for EW

Nov 2015CitigroupInitiates Coverage onSell
Oct 2015Cowen & CompanyInitiates Coverage onOutperform
Aug 2015Credit SuisseAssumesOutperform

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings


Related Articles (EW)

View Comments and Join the Discussion!

Get Benzinga's Newsletters